These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 9191873)

  • 21. PSK and OK-432-induced immunomodulation of inducible nitric oxide (NO) synthase gene expression in mouse peritoneal polymorphonuclear leukocytes and NO-mediated cytotoxicity.
    Asai K; Kato H; Hirose K; Akaogi K; Kimura S; Mukai S; Inoue M; Yamamura Y; Sano H; Sugino S; Yoshikawa T; Kondo M
    Immunopharmacol Immunotoxicol; 2000 May; 22(2):221-35. PubMed ID: 10952028
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunomodulatory effects of interferon-gamma in patients with metastatic malignant melanoma.
    Kopp WC; Smith JW; Ewel CH; Alvord WG; Main C; Guyre PM; Steis RG; Longo DL; Urba WJ
    J Immunother Emphasis Tumor Immunol; 1993 Apr; 13(3):181-90. PubMed ID: 8471592
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Enhancement of polymorphonuclear leukocyte (PMN) function by OK-432.
    Ueta E; Umazume M; Yamamoto T; Osaki T
    Int J Immunopharmacol; 1994 Jan; 16(1):7-17. PubMed ID: 8150558
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Streptococcal preparation OK-432 is a potent inducer of IL-12 and a T helper cell 1 dominant state.
    Fujimoto T; Duda RB; Szilvasi A; Chen X; Mai M; O'Donnell MA
    J Immunol; 1997 Jun; 158(12):5619-26. PubMed ID: 9190909
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Experimental study concerning safety dosage of OK-432 for intrauterine treatment.
    Ogita K; Taguchi T; Suita S
    Asian J Surg; 2006 Jul; 29(3):202-6. PubMed ID: 16877226
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Enhancement of anti-cancer immunity by a lipoteichoic-acid-related molecule isolated from a penicillin-killed group A Streptococcus.
    Okamoto M; Ohe G; Oshikawa T; Furuichi S; Nishikawa H; Tano T; Ahmed SU; Yoshida H; Moriya Y; Saito M; Sato M
    Cancer Immunol Immunother; 2001 Oct; 50(8):408-16. PubMed ID: 11726135
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of soluble factors derived from oral cancer cells on the production of interferon-γ from peripheral blood mononuclear cells following stimulation with OK-432.
    Ohe G; Sasai A; Uchida D; Tamatani T; Nagai H; Miyamoto Y
    Oncol Rep; 2013 Aug; 30(2):945-51. PubMed ID: 23685791
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunomodulatory function of interferon-gamma in patients with metastatic melanoma: results of a phase II-B trial in subjects with metastatic melanoma, ECOG study E 4987. Eastern Cooperative Oncology Group.
    Kirkwood JM; Bryant J; Schiller JH; Oken MM; Borden EC; Whiteside TL
    J Immunother; 1997 Mar; 20(2):146-57. PubMed ID: 9087387
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Control of endotoxin shock by the dried preparation of low virulent Streptococcus pyogenes OK-432.
    Nose M; Uzawa A; Nomura M; Ikarashi Y; Nakata Y; Akashi M; Suzuki G
    Cell Immunol; 1998 Sep; 188(2):97-104. PubMed ID: 9756639
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Streptococcal preparation OK-432 enhances the antitumor activity of CPT-11 by increasing Th1-cytokine production in mice.
    Wang X; Fujimoto T; Zhang B; Mai M
    Anticancer Res; 2001; 21(4A):2505-10. PubMed ID: 11724314
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Induction of Th1-type cytokines by lipoteichoic acid-related preparation isolated from OK-432, a penicillin-killed streptococcal agent.
    Okamoto M; Ohe G; Oshikawa T; Nishikawa H; Furuichi S; Yoshida H; Matsuno T; Saito M; Sato M
    Immunopharmacology; 2000 Sep; 49(3):363-76. PubMed ID: 10996034
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of 5'-DFUR and OK-432 on cytokines and thymidine phosphorylase in tumor tissue of gastric cancer patients.
    Ohwada S; Ogawa T; Izumi M; Inoue T; Teshigawara O; Ikeya T; Kusaba T; Roppongi T; Iino Y; Morishita Y
    Anticancer Res; 1997; 17(3C):2313-8. PubMed ID: 9216708
    [TBL] [Abstract][Full Text] [Related]  

  • 33. OK-432 synergizes with IFN-γ to confer dendritic cells with enhanced antitumor immunity.
    Pan K; Lv L; Zheng HX; Zhao JJ; Pan QZ; Li JJ; Weng DS; Wang DD; Jiang SS; Chang AE; Li Q; Xia JC
    Immunol Cell Biol; 2014 Mar; 92(3):263-74. PubMed ID: 24296809
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Recombinant human granulocyte colony-stimulating factor augments cytotoxicity of OK-432-induced polymorphonuclear leukocytes.
    Inoue M; Kato H; Mukai S; Kawahito Y; Asai K; Kimura S; Yamamura Y; Sano H; Sugino S; Kondo M
    Int J Immunopharmacol; 1994 Jan; 16(1):19-28. PubMed ID: 7512080
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mechanism of NK activation by OK-432 (Streptococcus pyogenes). I. Spontaneous release of NKCF and augmentation of NKCF production following stimulation with NK target cells.
    Bonavida B; Katz J; Hoshino T
    Cell Immunol; 1986 Oct; 102(1):126-35. PubMed ID: 3492275
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Involvement of Toll-like receptor 4 signaling in interferon-gamma production and antitumor effect by streptococcal agent OK-432.
    Okamoto M; Oshikawa T; Tano T; Ohe G; Furuichi S; Nishikawa H; Ahmed SU; Akashi S; Miyake K; Takeuchi O; Akira S; Moriya Y; Matsubara S; Ryoma Y; Saito M; Sato M
    J Natl Cancer Inst; 2003 Feb; 95(4):316-26. PubMed ID: 12591988
    [TBL] [Abstract][Full Text] [Related]  

  • 37. OK-432 and 5-fluorouracil, doxorubicin, and mitomycin C (FAM-P) versus FAM chemotherapy in patients with curatively resected gastric carcinoma: a randomized Phase III trial.
    Kim SY; Park HC; Yoon C; Yoon HJ; Choi YM; Cho KS
    Cancer; 1998 Nov; 83(10):2054-9. PubMed ID: 9827708
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antitumor effect of OK-432-derived DNA: one of the active constituents of OK-432, a streptococcal immunotherapeutic agent.
    Oshikawa T; Okamoto M; Tano T; Sasai A; Kan S; Moriya Y; Ryoma Y; Saito M; Akira S; Sato M
    J Immunother; 2006; 29(2):143-50. PubMed ID: 16531815
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Study on adjuvant immunochemotherapy with long-term OK-432 administration in colorectal cancer].
    Kikkawa N; Kawahara T
    Gan To Kagaku Ryoho; 1988 Jun; 15(6):1881-5. PubMed ID: 3382240
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Analysis of antitumor effects of OK-432 against syngeneic mouse fibrosarcoma: combination effect of OK-432 and recombinant lymphokines.
    Nanjo M; Moriya Y; Hashimoto S; Kataoka M; Saito M; Yoshida T; Ishida N
    Int J Immunopharmacol; 1991; 13(2-3):205-15. PubMed ID: 1906439
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.